Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 1356 Formulations in Healthy Volunteers
NCT02183363Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2007
- Primary completion
- May 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 hours. Started Feb 2007; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183363.